Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II data show safety and efficacy of OCS-02 in dry eye disease

Aug. 3, 2021

Discovery of SR-42667: a tau-SH3 interaction inhibitor that prevents Abeta toxicity

Aug. 3, 2021

Prometheus initiates phase IIa APOLLO-CD study of PRA-023 in Crohn's disease

Aug. 3, 2021

Dosing begins in phase I study of mRNA-6231

Aug. 3, 2021

FDA clears IND for phase I/II MARINA study of AOC-1001

Aug. 3, 2021

Ascentage Pharma discovers mutant GTPase KRAS inhibitors

Aug. 3, 2021

New CDK and TRK inhibitors identified at Hangzhou Innogate Pharma

Aug. 3, 2021

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

Aug. 3, 2021

Hovione Scientia describes ligand drug conjugates including BET inhibitors

Aug. 3, 2021

Vaxart's IND application for S-only oral tablet COVID-19 vaccine cleared in U.S.

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...